Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Evidence suggests that these medications exert protective effects through multiple physiological pathways, including modest reductions in systolic blood pressure, improvements in lipid metabolism, attenuation of inflammatory signaling, delayed gastric emptying, and significant weight reduction
A key differentiator of Mardrigals resmetirom is that in a pivotal Phase 3 trial, it achieved both primary endpoints of NASH resolution and reduction in fibrosis (MAESTRO-NASH), the two liver histological improvement endpoints the FDA has proposed as reasonably likely to predict clinical benefit
Bermdez-Pirela VJ, Cano C, Medina MT, et al
[1] Drge W, Breitkreutz R
Krishnan, A
US$ 26.69
US$ 29.43
US$ 28.36
